United States· US:72786-101_e27a3e07-438e-49d3-aae3-095e9379c7b4
OXBRYTA
A voxelotor product containing voxelotor, registered in United States by Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.. The same ATC class is registered in 8 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Voxelotor is registered in 8 of 19 countries.
Countries holding a registration under ATC B06AX03 (voxelotor), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 5 of them publish a price we can compare per daily dose
Voxelotor · ATC B06AX03
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Franceprice
- Ireland
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- VOXELOTOR
- Manufacturer
- Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
- Country
- United States (US)
- ATC code
- B06AX03
- ATC class
- Voxelotor
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11727861010190 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-101-01)
- ndc1172786-101-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
195 interactions on record for voxelotor.
Graded by severity as the source publishes them — 45 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Voxelotor · interactions on record
195 records
- 45 severe
- 142 moderate
- 8 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- DexamethasoneH02AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Voxelotor in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumOxbryta 500 mgPfizer Europe MA
- CzechiaOXBRYTAPfizer Europe MA EEIG, Bruxelles
- SpainOXBRYTA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPfizer Europe Ma Eeig
- FranceOXBRYTA 500 mg, comprimé pelliculéPFIZER EUROPE MA EEIG (BELGIQUE)
- PolandOxbrytaPfizer Europe MA EEIG
- SwedenOxbryta 500 mg Filmdragerad tablettPfizer Europe MA EEIG
- IrelandOxbrytaPfizer Europe MA EEIG
- United KingdomOxbryta 500mg tabletsPfizer Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Oxbryta
- Liechtenstein · Oxbryta
- Norway · Oxbryta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2461af03-eb13-4f23-8161-60a0e2d23066 GET /v1/drugs/2461af03-eb13-4f23-8161-60a0e2d23066?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "500",
"substance": "VOXELOTOR",
"productndc": "72786-101",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA213137",
"marketing_category": "NDA"
}See everything about voxelotor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.